Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B).

In this small study, AEs and tolerability of osimertinib plus selumetinib were as expected, based on previous studies. The combination demonstrated antitumor activity supportive of further investigation in patients with MET-negative, EGFRm advanced NSCLC, who had progressed on a previous EGFR-TKI.